CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
Speakers
Sample of Keynote Speakers and their Case Studies
CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
Fatima Bennai-Sanfourche
Sr. Director of QA & RA Compliance for Medical devices, Combination products, and eHealth
CASE STUDY
Navigating Opportunities and Challenges of Using Digital Tools Medical Devices in Drug Clinical Trials
Patient-centric approaches are required to ensure that patients have a single source of information for all their treatments and the related expert-curated medical information. Platforms can enable these patient-centric solutions while also offering opportunities for Pharmaceutical and digital health entrepreneurs to bring solutions to patients without major development effort.
The presentation will give an overview of the main topics and challenges of supply chain and logistics in an environment with dangerous chemicals and quality-sensitive products. You will get insights regarding a make-or-buy decision for storage and distribution and several other best practices. With regard to the actual “world of transformation”, there will also be interesting thoughts about deployment & transformation — especially how to find the right factors in scaling the final positioning of a so-called minimum viable product.
- 01Which digital tools or medical devices are currently used in drug clinical trials?
- 02How are they collectively improving the efficiency, accuracy, and patient-centricity of clinical trials?
- 03How do you address regulatory and compliance challenges?
- 04What are the challenges for the sponsor and the health institutions in using these tools?
- 05Can these digital tools reduce Costs and enhance the Efficiency of conducting and executing the studies?
CASE STUDY
Digital Health Solutions in Clinical Trials to Improve Patient Experience, Accelerate Timelines, and Improve Outcomes
Presentation on development of Remote Patient Monitoring (RPM), science-led and user-centric digital solutions to mitigate morbidity of high-grade toxicities and improve patient outcomes, decrease study costs/timelines, as well as increase sustainability.
Supply Chain Resilience:
Global Sourcing/Procurement (Chemical/Pharmaceutical vs Electronic Assembly Companies)
Manufacturing and Network Re-design (Chemical/Lubricants Company)
- 01Digital Patient Solutions (DPS) in cancer
- 02Remote Patient Monitoring (RPM) of Adverse Events of Special Interest (AESI) in clinical studies
Lenin Chaturvedi
Senior Vice President of Data, Digital & Technology, Plasma-Derived Therapies
CASE STUDY
Harnessing the Power of Digital Technologies to Transform the Journey of Potentially Life-Saving Therapies
Plasma-derived therapies (PDTs) are life-changing and life-sustaining medicines that people with rare and complex chronic diseases around the world rely on every day. Plasma is a scarce resource that cannot be made artificially, and hundreds of plasma donations – and sometimes over a thousand – are needed to make enough therapy for just one patient for one year. This is a complex, large-scale business in which growth in demand for therapies is outpacing supply – and patients’ lives are at stake. At Takeda, our priority is to ensure a sustained supply of PDTs for the patients worldwide who depend on them. This presentation will share more on how we harness data, digital, and technology (DD&T) to make every step of our end-to-end process better, faster, and more efficient – from using AI to advance operational efficiencies to developing novel device and digital solutions for patients.
- 01Improving the donation experience
- 02Improving manufacturing
- 03Improving the patient experience
CASE STUDY
7 Things to Avoid When Planning a Successful DTx Commercialisation
During the past 1.5 years, we have learned a lot about operating a DiGA start-up x Pharma collaboration. Even if we haven’t yet reached the success we aspired to, we did learn a lot along the way. We invite you to join our session so you can avoid the mistakes we have made.
In this session, we delve into the transformative world of omnichannel communication within global and local medical affairs. We will explore strategies and requirements for implementing an omnichannel approach, ensuring healthcare professionals have seamless access to diverse resources across multiple platforms. The session will highlight how leveraging data can refine and personalise communication methods, thus enhancing their impact on the target audience. Additionally, the presentation will address the importance of facilitating effective cross-functional communication among medical and commercial teams, especially in fostering a unified strategy. Finally, we will explore methods to tailor content and messaging to suit the diverse preferences of different healthcare professionals and stakeholders. This session promises to offer valuable insights and practical tools for anyone looking to enhance their communication strategies in the rapidly evolving healthcare sector.
- 01Market overview
- 02Seven things to avoid
- 03Promoting your DTx digitally only
- 04Using the same FF approach as for Rx
- 05Choosing the wrong partners (study, strategy,…)
Amelie Fassbender
Regional Medical Director – Business Development and Digital Therapeutics Lead
CASE STUDY
Patient-Centric Approaches and Social Impact
Emphasising the importance of user-centred design principles to create engaging, effective, and accessible DTx solutions for patients with varying needs and abilities.
Welcome to “Charting the Course: Our Influence on the HCP/Customer Engagement Trek”. Today, we embark on a journey to explore our impact on the ever-evolving landscape of healthcare professional (HCP) and customer engagement. In a world shaped by technology, ethics, and personalisation, our role as navigators of this journey is pivotal. Throughout this discourse, we’ll delve into key topics that define our approach, from leveraging technology to building meaningful connections. Join me as we navigate through these waters together, shaping not just outcomes, but the very fabric of trust and collaboration that underpins every meaningful engagement.
- 01Promoting health equity and access in DTx: Overcoming social and economic hurdles in DTx adoption
- 02Digital literacy and DTx education for patients: Strategies for empowering patients with the knowledge and skills needed to utilise DTx solutions effectively
- 03The role of patient advocacy groups in DTx development
- 04DTx for mental health & bridging the gap between need and access: Exploring how DTx can help address the growing mental health crisis by offering scalable and accessible solutions to improve mental well-being
Fatima Bennai-Sanfourche
Sr. Director of QA & RA Compliance for Medical devices, Combination products, and eHealth
CASE STUDY
Navigating Opportunities and Challenges of Using Digital Tools Medical Devices in Drug Clinical Trials
Patient-centric approaches are required to ensure that patients have a single source of information for all their treatments and the related expert-curated medical information. Platforms can enable these patient-centric solutions while also offering opportunities for Pharmaceutical and digital health entrepreneurs to bring solutions to patients without major development effort.
The presentation will give an overview of the main topics and challenges of supply chain and logistics in an environment with dangerous chemicals and quality-sensitive products. You will get insights regarding a make-or-buy decision for storage and distribution and several other best practices. With regard to the actual “world of transformation”, there will also be interesting thoughts about deployment & transformation — especially how to find the right factors in scaling the final positioning of a so-called minimum viable product.
- 01Which digital tools or medical devices are currently used in drug clinical trials?
- 02How are they collectively improving the efficiency, accuracy, and patient-centricity of clinical trials?
- 03How do you address regulatory and compliance challenges?
- 04What are the challenges for the sponsor and the health institutions in using these tools?
- 05Can these digital tools reduce Costs and enhance the Efficiency of conducting and executing the studies?
CASE STUDY
Digital Health Solutions in Clinical Trials to Improve Patient Experience, Accelerate Timelines, and Improve Outcomes
Presentation on development of Remote Patient Monitoring (RPM), science-led and user-centric digital solutions to mitigate morbidity of high-grade toxicities and improve patient outcomes, decrease study costs/timelines, as well as increase sustainability.
Supply Chain Resilience:
Global Sourcing/Procurement (Chemical/Pharmaceutical vs Electronic Assembly Companies)
Manufacturing and Network Re-design (Chemical/Lubricants Company)
- 01Digital Patient Solutions (DPS) in cancer
- 02Remote Patient Monitoring (RPM) of Adverse Events of Special Interest (AESI) in clinical studies
Amelie Fassbender
Regional Medical Director – Business Development and Digital Therapeutics Lead
CASE STUDY
Patient-Centric Approaches and Social Impact
Emphasising the importance of user-centred design principles to create engaging, effective, and accessible DTx solutions for patients with varying needs and abilities.
Welcome to “Charting the Course: Our Influence on the HCP/Customer Engagement Trek”. Today, we embark on a journey to explore our impact on the ever-evolving landscape of healthcare professional (HCP) and customer engagement. In a world shaped by technology, ethics, and personalisation, our role as navigators of this journey is pivotal. Throughout this discourse, we’ll delve into key topics that define our approach, from leveraging technology to building meaningful connections. Join me as we navigate through these waters together, shaping not just outcomes, but the very fabric of trust and collaboration that underpins every meaningful engagement.
- 01Promoting health equity and access in DTx: Overcoming social and economic hurdles in DTx adoption
- 02Digital literacy and DTx education for patients: Strategies for empowering patients with the knowledge and skills needed to utilise DTx solutions effectively
- 03The role of patient advocacy groups in DTx development
- 04DTx for mental health & bridging the gap between need and access: Exploring how DTx can help address the growing mental health crisis by offering scalable and accessible solutions to improve mental well-being
Lenin Chaturvedi
Senior Vice President of Data, Digital & Technology, Plasma-Derived Therapies
CASE STUDY
Harnessing the Power of Digital Technologies to Transform the Journey of Potentially Life-Saving Therapies
Plasma-derived therapies (PDTs) are life-changing and life-sustaining medicines that people with rare and complex chronic diseases around the world rely on every day. Plasma is a scarce resource that cannot be made artificially, and hundreds of plasma donations – and sometimes over a thousand – are needed to make enough therapy for just one patient for one year. This is a complex, large-scale business in which growth in demand for therapies is outpacing supply – and patients’ lives are at stake. At Takeda, our priority is to ensure a sustained supply of PDTs for the patients worldwide who depend on them. This presentation will share more on how we harness data, digital, and technology (DD&T) to make every step of our end-to-end process better, faster, and more efficient – from using AI to advance operational efficiencies to developing novel device and digital solutions for patients.
- 01Improving the donation experience
- 02Improving manufacturing
- 03Improving the patient experience
CASE STUDY
7 Things to Avoid When Planning a Successful DTx Commercialisation
During the past 1.5 years, we have learned a lot about operating a DiGA start-up x Pharma collaboration. Even if we haven’t yet reached the success we aspired to, we did learn a lot along the way. We invite you to join our session so you can avoid the mistakes we have made.
In this session, we delve into the transformative world of omnichannel communication within global and local medical affairs. We will explore strategies and requirements for implementing an omnichannel approach, ensuring healthcare professionals have seamless access to diverse resources across multiple platforms. The session will highlight how leveraging data can refine and personalise communication methods, thus enhancing their impact on the target audience. Additionally, the presentation will address the importance of facilitating effective cross-functional communication among medical and commercial teams, especially in fostering a unified strategy. Finally, we will explore methods to tailor content and messaging to suit the diverse preferences of different healthcare professionals and stakeholders. This session promises to offer valuable insights and practical tools for anyone looking to enhance their communication strategies in the rapidly evolving healthcare sector.
- 01Market overview
- 02Seven things to avoid
- 03Promoting your DTx digitally only
- 04Using the same FF approach as for Rx
- 05Choosing the wrong partners (study, strategy,…)
Fatima Bennai-Sanfourche
Sr. Director of QA & RA Compliance for Medical devices, Combination products, and eHealth
CASE STUDY
Navigating Opportunities and Challenges of Using Digital Tools Medical Devices in Drug Clinical Trials
Patient-centric approaches are required to ensure that patients have a single source of information for all their treatments and the related expert-curated medical information. Platforms can enable these patient-centric solutions while also offering opportunities for Pharmaceutical and digital health entrepreneurs to bring solutions to patients without major development effort.
The presentation will give an overview of the main topics and challenges of supply chain and logistics in an environment with dangerous chemicals and quality-sensitive products. You will get insights regarding a make-or-buy decision for storage and distribution and several other best practices. With regard to the actual “world of transformation”, there will also be interesting thoughts about deployment & transformation — especially how to find the right factors in scaling the final positioning of a so-called minimum viable product.
- 01Which digital tools or medical devices are currently used in drug clinical trials?
- 02How are they collectively improving the efficiency, accuracy, and patient-centricity of clinical trials?
- 03How do you address regulatory and compliance challenges?
- 04What are the challenges for the sponsor and the health institutions in using these tools?
- 05Can these digital tools reduce Costs and enhance the Efficiency of conducting and executing the studies?
CASE STUDY
Digital Health Solutions in Clinical Trials to Improve Patient Experience, Accelerate Timelines, and Improve Outcomes
Presentation on development of Remote Patient Monitoring (RPM), science-led and user-centric digital solutions to mitigate morbidity of high-grade toxicities and improve patient outcomes, decrease study costs/timelines, as well as increase sustainability.
Supply Chain Resilience:
Global Sourcing/Procurement (Chemical/Pharmaceutical vs Electronic Assembly Companies)
Manufacturing and Network Re-design (Chemical/Lubricants Company)
- 01Digital Patient Solutions (DPS) in cancer
- 02Remote Patient Monitoring (RPM) of Adverse Events of Special Interest (AESI) in clinical studies
Lenin Chaturvedi
Senior Vice President of Data, Digital & Technology, Plasma-Derived Therapies
CASE STUDY
Harnessing the Power of Digital Technologies to Transform the Journey of Potentially Life-Saving Therapies
Plasma-derived therapies (PDTs) are life-changing and life-sustaining medicines that people with rare and complex chronic diseases around the world rely on every day. Plasma is a scarce resource that cannot be made artificially, and hundreds of plasma donations – and sometimes over a thousand – are needed to make enough therapy for just one patient for one year. This is a complex, large-scale business in which growth in demand for therapies is outpacing supply – and patients’ lives are at stake. At Takeda, our priority is to ensure a sustained supply of PDTs for the patients worldwide who depend on them. This presentation will share more on how we harness data, digital, and technology (DD&T) to make every step of our end-to-end process better, faster, and more efficient – from using AI to advance operational efficiencies to developing novel device and digital solutions for patients.
- 01Improving the donation experience
- 02Improving manufacturing
- 03Improving the patient experience
CASE STUDY
7 Things to Avoid When Planning a Successful DTx Commercialisation
During the past 1.5 years, we have learned a lot about operating a DiGA start-up x Pharma collaboration. Even if we haven’t yet reached the success we aspired to, we did learn a lot along the way. We invite you to join our session so you can avoid the mistakes we have made.
In this session, we delve into the transformative world of omnichannel communication within global and local medical affairs. We will explore strategies and requirements for implementing an omnichannel approach, ensuring healthcare professionals have seamless access to diverse resources across multiple platforms. The session will highlight how leveraging data can refine and personalise communication methods, thus enhancing their impact on the target audience. Additionally, the presentation will address the importance of facilitating effective cross-functional communication among medical and commercial teams, especially in fostering a unified strategy. Finally, we will explore methods to tailor content and messaging to suit the diverse preferences of different healthcare professionals and stakeholders. This session promises to offer valuable insights and practical tools for anyone looking to enhance their communication strategies in the rapidly evolving healthcare sector.
- 01Market overview
- 02Seven things to avoid
- 03Promoting your DTx digitally only
- 04Using the same FF approach as for Rx
- 05Choosing the wrong partners (study, strategy,…)
Amelie Fassbender
Regional Medical Director – Business Development and Digital Therapeutics Lead
CASE STUDY
Patient-Centric Approaches and Social Impact
Emphasising the importance of user-centred design principles to create engaging, effective, and accessible DTx solutions for patients with varying needs and abilities.
Welcome to “Charting the Course: Our Influence on the HCP/Customer Engagement Trek”. Today, we embark on a journey to explore our impact on the ever-evolving landscape of healthcare professional (HCP) and customer engagement. In a world shaped by technology, ethics, and personalisation, our role as navigators of this journey is pivotal. Throughout this discourse, we’ll delve into key topics that define our approach, from leveraging technology to building meaningful connections. Join me as we navigate through these waters together, shaping not just outcomes, but the very fabric of trust and collaboration that underpins every meaningful engagement.
- 01Promoting health equity and access in DTx: Overcoming social and economic hurdles in DTx adoption
- 02Digital literacy and DTx education for patients: Strategies for empowering patients with the knowledge and skills needed to utilise DTx solutions effectively
- 03The role of patient advocacy groups in DTx development
- 04DTx for mental health & bridging the gap between need and access: Exploring how DTx can help address the growing mental health crisis by offering scalable and accessible solutions to improve mental well-being